BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI)

SOL #: ARPA-H-SOL-26-149Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Washington, DC, 20005, United States

Place of Performance

Washington, DC

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

Health R&D Services; Health Care Services; Experimental Development (AN13)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 27, 2026
2
Last Updated
Feb 18, 2026
3
Submission Deadline
Apr 15, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program. This initiative seeks to fundamentally transform therapeutic approaches to protein dysfunction by controlling protein folding and preventing aggregation—the root cause of many chronic and degenerative illnesses. Solution Summaries are due March 4, 2026, and Full Proposals are due April 15, 2026.

Scope of Work

The program is divided into two primary Technical Areas (TAs):

  • Technical Area 1 (TA1): Establish the "molecular grammar" of Intrinsically Disordered Regions (IDRs). Performers will develop computational and experimental methods to determine the sequence features and environmental conditions that regulate IDR behavior and biomolecular condensates.
  • Technical Area 2 (TA2): Validate TA1 foundational models to develop detection and therapeutic applications. This includes creating methods to reverse protein aggregation, restore function, and identify clinical indicators for early detection. Solutions must target at least one rare and one non-rare disease.

Contract & Timeline

  • Type: Multiple Other Transaction (OT) Agreements
  • Duration: Two phases: Phase 1 (0–24 months) and Phase 2 (25–48 months)
  • Set-Aside: None (Open to all responsible sources, including universities, non-profits, and businesses)
  • Key Deadlines:
    • Proposers’ Day: February 20, 2026
    • Solution Summaries: March 4, 2026
    • Full Proposals: April 15, 2026

Evaluation

Proposals will be evaluated based on:

  1. Overall Scientific and Technical Merit
  2. Proposer's Capabilities and Related Experience
  3. Potential Contribution to the ARPA-H Mission and User Experience
  4. Assessment of Proposed Cost/Price

Additional Notes

This is a two-step submission process. Proposers must first submit a Solution Summary; full proposals are optional and based on encouragement from the government review. Performers are required to provide 5-year and 10-year commercialization plans and adhere to open data sharing requirements for TA1 activities.

People

Points of Contact

The BIOGAMI TeamPRIMARY

Files

Files

No files attached to this opportunity

Versions

Version 2
Solicitation
Posted: Feb 18, 2026
View
Version 1Viewing
Solicitation
Posted: Jan 27, 2026
BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) | GovScope